Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Axitinib in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma
NCT03839498Phase 2Active, not recruiting
- Sponsor
- Columbia University
- Start
- Jan 2019
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of axitinib in pheochromocytoma and Paraganglioma (PGL), sponsored by Columbia University. Primary endpoint: Response Rate at 16 weeks. Started Jan 2019; status: active, not recruiting.
02
Drugs
axitinib
03
Conditions
pheochromocytomaParaganglioma (PGL)
Beyond the preview
Go deeper on NCT03839498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03839498.